血清SIL-2R、CYFRA21-1和TNF-α水平在吉西他滨联合铂类化疗治疗晚期非小细胞肺癌患者中的临床意义  

Clinical significance of SIL-2R,CYFRA21-1 and TNF-a levels in the gemcitabine plus platinum chemotherapy of advanced non-small cell lung cancer patients

作　　者：姜世涛[1] 涂建成[2] 喻明霞[1] 

机构地区：[1]武汉大学中南医院基因诊断中心武汉大学中南医院检验科,武汉430071 [2]武汉大学第二临床学院检验系,武汉430071

出　　处：《世界临床药物》2016年第9期621-624,共4页World Clinical Drug

基　　金：国家973项目(编号:2012CB720600);子课题(编号:2012CB720605);湖北省卫生和计划生育委员会科研项目青年人才项目(编号:WJ2015Q021)

摘　　要：目的探讨晚期非小细胞肺癌（NSCLC）患者化疗前后血清可溶性白介素-2受体（SIL-2R）、细胞角蛋白19片段（CYFRA21-1）、肿瘤坏死因子-α（TNF-α）水平变化及其与化疗疗效的关系。方法采用ELISA法测定58例晚期NSCLC患者（治疗组）及60例健康者（对照组）血清SIL-2R、CYFRA21-1和TNF-α水平,分析治疗前后血清SIL-2R、CYFRA21-1和TNF-α水平变化幅度与患者化疗疗效的关系。结果化疗后,治疗组客观缓解率（ORR）为25.86%,疾病控制率（DCR）为60.34%,无进展生存期（PFS）为3.9（0~7.5）个月。相关性分析显示,化疗后SIL-2R、CYFRA21-1和TNF-α水平下降程度与PFS呈明显相关性（r=0.653,0.735,0.591,P〈0.05）。结论晚期NSCLC患者化疗后血清SIL-2R、CYFRA21-1和TNF-α水平显著降低,其下降幅度与PFS呈显著相关性,可作为晚期NSCLC患者化疗疗效的评价指标。Objective To explore the changes of serum soluble interleukin-2 receptor（SIL-2R）,cytokeratin 19 fragments（CYFRA21-1） and tumor necrosis factor-α（TNF-α） of the patients with advanced non-small cell lung cancer（NSCLC）before and after chemotherapy,and their correlation with the efficacy of chemotherapy.Methods The levels of serum SIL-2R,CYFRA21-1,TNF-α in 58 cases of advanced NSCLC patients（treatment group） and 60 healthy volunteers（control group） were determined by ELISA.The correlation between the indexes and the curative effect before and after treatment was analyzed.Results After chemotherapy,the objective remission rate（ORR） in treatment group was 25.86%,the disease control rate（DCR） was 60.34%,and the progression free survival（PFS） was 3.9（0~7.5） months.Correlation analysis showed that the proportion of SIL-2R,CYFRA21-1,TNF-α after chemotherapy had a significantly correlation with the PFS（r=0.653,0.735,0.591,P〈0.05）.Conclusion The serum SIL-2R,CYFRA21-1 and TNF-α levels in the advanced NSCLC patients received chemotherapy are significantly decreased and significantly correlated with PFS,which can be used as the evaluation index of chemotherapy efficacy in advanced NSCLC patients.

关 键 词：非小细胞肺癌(NSCLC) 可溶性白介素-2受体(SIL-2R) 细胞角蛋白19片段(CYFRA21-1) 肿瘤坏死因子-α(TNF-α) 

分 类 号：R734.2[医药卫生—肿瘤] R979.1[医药卫生—临床医学]